CaldrionPrivate CreditSearchRequest financing

TransactionAsset-based & corporate lending

Project Beacon: receivables facility for a management buyout, Reston

An $18.0M revolver on federal receivables that made a founder-to-management buyout work as a stock purchase, with a seller note subordinated behind us.

A closed Caldrion loan, shown under its project code name. The borrower and sponsor are not named. Terms are as of closing; returns are our underwriting targets, not realized results.

Receivables ABL for a buyout · $18.0M · drawn = 65% of receivables · S+600

At a glance

BorrowerFederal IT and engineering services contractor; 420 employees; $96M revenue; $8.6M EBITDA; 85% prime contracts with civilian agencies and the Defense Department
TransactionManagement buyout of the 71-year-old founder at a $68M enterprise value (7.9x EBITDA)
Facility$18.0M revolver, $14.0M drawn at close
CollateralFirst lien on all assets, mainly billed and unbilled government receivables
LeverageThe drawn amount is 65% of gross receivables; senior leverage is 1.6x EBITDA
Term36 months
PricingS+600 (≈9.75%); 0.375% unused fee; 1.25% origination

The situation

The founder wanted to retire, and the COO, CFO and an independent sponsor wanted to buy the company. Banks offered cash-flow loans with senior leverage caps and covenants that didn’t work with a seller note in the structure. One bank also wanted the deal done as an asset purchase, which would have required novating every federal contract to a new entity, a process that takes months.

Capital structure

Capital structure$MCumulative leverage
Caldrion revolver (drawn)14.01.6x
Seller note (subordinated)16.03.5x
Independent sponsor equity26.0
Management rollover equity12.0
Total68.0

Borrowing base

Borrowing baseGrossAdvanceAvailability
Billed receivables from federal agencies$13.8M90%$12.4M
Billed receivables as a subcontractor to primes$2.4M85%$2.0M
Unbilled receivables (under 45 days, billable)$5.5M75%$4.1M
Availability$18.5M, capped at the $18.0M commitment

Structure

  • The deal is a stock purchase, so the contracts stay in the same legal entity and no novation is needed.
  • Under the Assignment of Claims Act, formal notices are filed on the largest prime contracts (about 80% of billings), so those agencies pay into our account. Notices on the rest spring in later if needed.
  • Payments from prime contractors go to a lockbox we control.
  • Under the subordination agreement, the seller note’s interest is paid in cash only while excess availability is above $3M and there is no default. Its principal is blocked until we are repaid, and the seller can’t take enforcement action.
  • No single agency or contract can exceed 25% of eligible receivables without approval.
  • The covenants are $2.0M of minimum excess availability and a 1.1x fixed-charge coverage test that springs in only if availability tightens. The company reports backlog and recompetes monthly and must keep a DCAA-compliant accounting system.
  • A funding-lapse playbook: during a federal shutdown, unbilled receivables stay eligible for 60 days, and availability can be raised temporarily by $2M. A shutdown delays government payment but rarely impairs it, as the fall 2025 shutdown showed.

Risks and mitigants

RiskMitigant
A contract is lost at recompete72% of revenue is under contracts with options through 2029; the facility shrinks automatically as receivables shrink
Shutdowns or slow paymentAvailability headroom; shutdown provisions
Small-business status changesThe company already competes in full-and-open procurements, so it has no set-aside cliff
Contracts can’t be assignedAssignment of Claims Act filings

Exit and returns, as underwritten

After 18–24 months of clean performance and a partial paydown of the seller note, a bank refinances the facility at a lower cost, or a larger government-services consolidator buys the company. Target: about a 10.6% IRR.

Downside

If the company loses its largest contract (18% of revenue), receivables shrink by about $4M and availability falls to about $15M, still above the $14M drawn. Because the loan is repaid as receivables collect, it winds itself down, and federal receivables carry very little default risk.

See all our transactions, the twelve loans compared and our criteria.

This case study is provided for information only. It is not an offer of securities or investment advice, and targeted results do not indicate future results.

Insights

More to read.

Investment perspective

Twelve loans: the common thread

Twelve closed Caldrion loans at a glance, the five ingredients they share, and the loans we pass on.

Caldrion Private Credit

Transaction

Project Meridian: pharma royalty monetization

A $30.0M loan against a 6% royalty on an approved orphan drug, which funded a biotech’s Phase 2 trial without dilutive equity or selling the royalty outright.

Caldrion Private Credit